| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
FLGT Stock Overview
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information.
Fulgent Genetics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$60.70 |
| 52 Week High | US$189.89 |
| 52 Week Low | US$60.59 |
| Beta | 1.34 |
| 1 Month Change | -41.72% |
| 3 Month Change | -27.79% |
| 1 Year Change | -12.33% |
| 3 Year Change | 1,321.55% |
| 5 Year Change | 366.92% |
| Change since IPO | 561.22% |
Recent News & Updates
Fulgent Genetics: Improving Outlook, But Shares Aren't Quite A Buy
I was bearish on Fulgent in 2021, expecting the stock to slump as Covid-19 testing revenues faded. Delta and omicron have extended the window for testing dramatically. Even so, Fulgent stock has underwhelmed in recent months. The company's business has improved enough to mitigate much of the bearish case, however I'm still no more than neutral on the stock.
Fulgent Genetics: Undervalued, High Growth, And A COVID Hedge To Boot
Fulgent's COVID testing business isn't going away any time soon and will continue to gush cash for reinvestment, even allowing for melting ice cube scenarios. Fulgent's core business continues to grow at a high rate and has benefited from COVID testing related capitalization. Fulgent, with its brilliant founder, strong insider ownership, plummeting EV, and high growth core business, is undervalued.
Shareholder Returns
| FLGT | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -24.1% | -3.5% | -6.1% |
| 1Y | -12.3% | 12.7% | 4.2% |
Return vs Industry: FLGT underperformed the US Healthcare industry which returned 12.8% over the past year.
Return vs Market: FLGT underperformed the US Market which returned 6.6% over the past year.
Price Volatility
| FLGT volatility | |
|---|---|
| FLGT Average Weekly Movement | 9.8% |
| Healthcare Industry Average Movement | 7.9% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.4% |
Stable Share Price: FLGT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: FLGT's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 626 | Ming Hsieh | https://www.fulgentgenetics.com |
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions.
Fulgent Genetics Fundamentals Summary
| FLGT fundamental statistics | |
|---|---|
| Market Cap | US$1.81b |
| Earnings (TTM) | US$569.33m |
| Revenue (TTM) | US$1.04b |
3.2x
P/E Ratio1.7x
P/S RatioIs FLGT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FLGT income statement (TTM) | |
|---|---|
| Revenue | US$1.04b |
| Cost of Revenue | US$205.17m |
| Gross Profit | US$830.72m |
| Expenses | US$261.39m |
| Earnings | US$569.33m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 19.08 |
| Gross Margin | 80.19% |
| Net Profit Margin | 54.96% |
| Debt/Equity Ratio | 2.0% |
How did FLGT perform over the long term?
See historical performance and comparisonValuation
Is Fulgent Genetics undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: FLGT ($60.7) is trading below our estimate of fair value ($5863.67)
Significantly Below Fair Value: FLGT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: FLGT is good value based on its PE Ratio (3.2x) compared to the US Healthcare industry average (20.3x).
PE vs Market: FLGT is good value based on its PE Ratio (3.2x) compared to the US market (16.7x).
Price to Earnings Growth Ratio
PEG Ratio: FLGT's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: FLGT is good value based on its PB Ratio (1.7x) compared to the US Healthcare industry average (2.6x).
Future Growth
How is Fulgent Genetics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
-69.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FLGT's earnings are forecast to decline over the next 3 years (-69.3% per year).
Earnings vs Market: FLGT's earnings are forecast to decline over the next 3 years (-69.3% per year).
High Growth Earnings: FLGT's earnings are forecast to decline over the next 3 years.
Revenue vs Market: FLGT's revenue is expected to decline over the next 3 years (-40.6% per year).
High Growth Revenue: FLGT's revenue is forecast to decline over the next 3 years (-40.6% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FLGT's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Fulgent Genetics performed over the past 5 years?
94.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FLGT has high quality earnings.
Growing Profit Margin: FLGT's current net profit margins (55%) are higher than last year (35.3%).
Past Earnings Growth Analysis
Earnings Trend: FLGT has become profitable over the past 5 years, growing earnings by 94% per year.
Accelerating Growth: FLGT's earnings growth over the past year (1093.4%) exceeds its 5-year average (94% per year).
Earnings vs Industry: FLGT earnings growth over the past year (1093.4%) exceeded the Healthcare industry 32.5%.
Return on Equity
High ROE: FLGT's Return on Equity (54.5%) is considered outstanding.
Financial Health
How is Fulgent Genetics's financial position?
Financial Position Analysis
Short Term Liabilities: FLGT's short term assets ($622.8M) exceed its short term liabilities ($147.2M).
Long Term Liabilities: FLGT's short term assets ($622.8M) exceed its long term liabilities ($13.1M).
Debt to Equity History and Analysis
Debt Level: FLGT has more cash than its total debt.
Reducing Debt: Insufficient data to determine if FLGT's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: FLGT's debt is well covered by operating cash flow (2829.6%).
Interest Coverage: FLGT earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Fulgent Genetics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FLGT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FLGT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FLGT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FLGT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FLGT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.5yrs
Average management tenure
CEO
Ming Hsieh (65 yo)
5.67yrs
Tenure
US$248,000
Compensation
Mr. Ming Hsieh has been an Independent Director of Fortinet, Inc. since April 2013. He is the Founder of Fulgent Genetics, Inc. and has been its President & Chief Executive Officer since May 2016 and serve...
CEO Compensation Analysis
Compensation vs Market: Ming's total compensation ($USD248.00K) is below average for companies of similar size in the US market ($USD3.73M).
Compensation vs Earnings: Ming's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: FLGT's management team is considered experienced (4.5 years average tenure).
Board Members
Experienced Board: FLGT's board of directors are considered experienced (5.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: FLGT insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.9%.
Top Shareholders
Company Information
Fulgent Genetics, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Fulgent Genetics, Inc.
- Ticker: FLGT
- Exchange: NasdaqGM
- Founded: 2011
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: US$1.811b
- Shares outstanding: 29.83m
- Website: https://www.fulgentgenetics.com
Number of Employees
Location
- Fulgent Genetics, Inc.
- 4978 Santa Anita Avenue
- Temple City
- California
- 91780
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/21 23:55 |
| End of Day Share Price | 2022/01/21 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.